Cumberland announces ifetroban NDA filing plan after shares plummet

Jonathan Block

• After shares declined almost 49% in Monday's trading session, Cumberland Pharmaceuticals (CPIX) said it will file an NDA for cardiomyopathy associated with Duchenne muscular dystrophy candidate ifetroban.
• The company held a pre-NDA meeting with the US FDA recently and intends to

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.